Gilead Sciences (GILD) Treasury Shares (2012 - 2025)
Gilead Sciences (GILD) posted Treasury Shares of $17.8 million for Q4 2025, down 18.35% quarter-over-quarter from $21.8 million in Q4 2024, and down 18.35% year-on-year from $21.8 million in Q4 2024.
Gilead Sciences (GILD) Treasury Shares (2012 - 2025) Analysis & Trends
Gilead Sciences (GILD) has reported Treasury Shares for 14 consecutive years, with $17.8 million the latest figure, recorded in Q4 2025.
- Treasury Shares for Q4 2025 came in at $17.8 million, down 18.35% year-over-year; the trailing twelve-month figure through Dec 2025 was $17.8 million (down 18.35% YoY), and the FY2025 annual result was $17.8 million, down 18.35% from the prior year.
- Treasury Shares was $17.8 million for Q4 2025 at Gilead Sciences, down from $21.8 million in the prior quarter.
- Over five years, Treasury Shares peaked at $22.7 million in Q4 2023 and troughed at $1.0 million in Q2 2022.
- Average Treasury Shares over 5 years is $9.6 million, with a median of $7.0 million recorded in 2021.
- Year-over-year, Treasury Shares jumped 600.0% in 2021 and tumbled 85.71% in 2022.
- Over 5 years, Treasury Shares stood at $8.0 million in 2021, then jumped by 137.5% to $19.0 million in 2022, then gained by 19.47% to $22.7 million in 2023, then retreated by 3.96% to $21.8 million in 2024, then fell by 18.35% to $17.8 million in 2025.
- Per Business Quant data, the three most recent Treasury Shares figures were $17.8 million in Q4 2025, $21.8 million in Q4 2024, and $4.0 million in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 3.01 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 76.26 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 10.61 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 1.11 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 3.94 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | -47.00 Mn |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 2.98 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 17.80 Mn |
| Dec 31, 2025 | 17.80 Mn |
| Dec 31, 2024 | 21.80 Mn |
| Dec 31, 2024 | 21.80 Mn |
| Sep 30, 2024 | 4.00 Mn |
| Sep 30, 2024 | 4.00 Mn |
| Jun 30, 2024 | 2.00 Mn |
| Jun 30, 2024 | 2.00 Mn |
| Mar 31, 2024 | 5.00 Mn |
| Mar 31, 2024 | 5.00 Mn |
| Dec 31, 2023 | 22.70 Mn |
| Dec 31, 2023 | 22.70 Mn |
| Sep 30, 2023 | 11.00 Mn |
| Sep 30, 2023 | 11.00 Mn |
| Jun 30, 2023 | 7.00 Mn |
| Jun 30, 2023 | 7.00 Mn |
| Mar 31, 2023 | 5.00 Mn |
| Mar 31, 2023 | 5.00 Mn |
| Dec 31, 2022 | 19.00 Mn |
| Dec 31, 2022 | 19.00 Mn |